Influence of L-Carnitine supplementation on serum lipid profile in Hemodialysis Patients: A systematic review and meta-analysis

Kidney and Blood Pressure Research

Volumn 38, Issue 1, 2014, Pages 31-41

  Huang, Haohai ^a   Song, Lijun ^a   Zhang, Hua ^a   Zhang, Hanbin ^a   Zhang, Jiping ^b   Zhao, Wenchang ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Second People's Hospital of Foshan   (China)

Author keywords

Hemodialysis; L Carnitine; Meta Analysis

Indexed keywords

CARNITINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; VITAMIN B COMPLEX;

CHOLESTEROL BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFICACY; END STAGE RENAL DISEASE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPOPROTEINEMIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; DRUG EFFECT; HEMODIALYSIS; INTERVENTION STUDY; KIDNEY DISEASE; ANIMAL; BLOOD; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY;

ANIMALS; CARNITINE; DIETARY SUPPLEMENTS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY; VITAMIN B COMPLEX;

EID: 84893639889     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355751     Document Type: Review

References (34)

1. Elliott RW: Demographics of the older adult and chronic kidney disease: a literature review. Nephrol Nurs J 2012;39:491-496; quiz 497.
2. Kletzmayr J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17:S25-29.
3. Cheung AK: Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 2009;4:S95-101.
4. Borum PR: Carnitine. Annu Rev Nutr 1983;3:233-259.
5. Carter AL, Abney TO, Lapp DF: Biosynthesis and metabolism of carnitine. J Child Neurol 1995;10:S3-7.
6. Mitwalli AH, Al-Wakeel JS, Alam A, Tarif N, Abu-Aisha H, Rashed M, Al Nahed N: L-carnitine supplementation in hemodialysis patients. Saudi J Kidney Dis Transpl 2005;16:17-22.
7. Irat AM, Aktan F, Ozansoy G: Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389-1395.
8. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N: L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001;44:235-242.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
11. Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-989.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
13. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
14. Guarnieri GF, Ranieri F, Toigo G, Vasile A, Ciman M, Rizzoli V, Moracchiello M, Campanacci L: Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr 1980;33:1489-1492.
15. Weschler A, Aviram M, Levin M, Better OS, Brook JG: High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 1984;38:120-124.
16. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H: Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest 1985;45:179-184.
17. Yderstraede KB, Pedersen FB, Dragsholt C, Trostmann A, Laier E, Larsen HF: The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis. Nephrol Dial Transplant 1987;1:238-241.
18. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD: Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990;38:904-911.
19. Labonia WD: L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995;26:757-764.
20. Vaux EC, Taylor DJ, Altmann P, Rajagopalan B, Graham K, Cooper R, Bonomo Y, Styles P: Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004;97:c41-48.
21. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S: Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on healthrelated quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 2006;60:143-153.
22. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D: Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006;21:3211-3214.
23. Shakeri A, Tabibi H, Hedayati M: Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 2010;14:498-504.
24. Suchitra MM, Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, Sivakumar V, Rao PV: The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2011;22:1155-1159.
25. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, Basir Ghafoori H, Emami Naini P: Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial. J Nutr Metab 2012;2012:510483.
26. Hurot JM, Cucherat M, Haugh M, Fouque D: Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002;13:708-714.
27. Pasternack A, Leino T, Solakivi-Jaakkola T, Huttunen JK, Ehnholm C: Effect of furosemide on the lipid abnormalities in chronic renal failure. Acta Med Scand 1983;214:153-157.
28. Campbell N, Brant R, Stalts H, Stone J, Mahallati H: Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 1998;158:1461-1463.
29. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984;74:1890-1894.
30. Macdougall IC, Geisser P: Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 2013;7:9-22.
31. Badimon L, Vilahur G: LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 2012;1254:18-32.
32. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M: Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997;76:7-14.
33. Homma K, Homma Y, Shiina Y, Wakino S, Suzuki M, Fujishima S, Hayashi K, Hori S, Itoh H: Skew of Plasma Low-and High-Density Lipoprotein Distributions to Less Dense Subfractions in Normotriglyceridemic Chronic Kidney Disease Patients on Maintenance Hemodialysis Treatment. Nephron Clin Pract 2013;123:41-45.
34. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y: Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 2001;38:S30-33.